desferrithiocin and beta-Thalassemia

desferrithiocin has been researched along with beta-Thalassemia* in 1 studies

Trials

1 trial(s) available for desferrithiocin and beta-Thalassemia

Article	Year
Safety and pharmacokinetics of the oral iron chelator SP-420 in β-thalassemia. American journal of hematology, 2017, Volume: 92, Issue:12 Our phase I, open-label, multi-center, dose-escalation study evaluated the pharmacokinetics (PK) of SP-420, a tridentate oral iron chelating agent of the desferrithiocin class, in patients with transfusion dependent β-thalassemia. SP-420 was administered as a single dose of 1.5 (n = 3), 3 (n = 3), 6 (n = 3), 12 (n = 3), and 24 (n = 6) mg/kg or as a twice-daily dose of 9 mg/kg (n = 6) over 14-28 days. There was a near dose-linear increase in the mean plasma SP-420 concentrations and in the mean values for C Topics: Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Cyclohexanones; Dihydropyridines; Dose-Response Relationship, Drug; Humans; Iron Chelating Agents; Kidney Diseases; Middle Aged; Siderophores; Thiazoles; Young Adult	2017

Article

Year

Safety and pharmacokinetics of the oral iron chelator SP-420 in β-thalassemia.

American journal of hematology, 2017, Volume: 92, Issue:12

Our phase I, open-label, multi-center, dose-escalation study evaluated the pharmacokinetics (PK) of SP-420, a tridentate oral iron chelating agent of the desferrithiocin class, in patients with transfusion dependent β-thalassemia. SP-420 was administered as a single dose of 1.5 (n = 3), 3 (n = 3), 6 (n = 3), 12 (n = 3), and 24 (n = 6) mg/kg or as a twice-daily dose of 9 mg/kg (n = 6) over 14-28 days. There was a near dose-linear increase in the mean plasma SP-420 concentrations and in the mean values for C

Topics: Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Cyclohexanones; Dihydropyridines; Dose-Response Relationship, Drug; Humans; Iron Chelating Agents; Kidney Diseases; Middle Aged; Siderophores; Thiazoles; Young Adult

2017